Compare NRDS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDS | DCTH |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.6M | 578.4M |
| IPO Year | 2021 | 2015 |
| Metric | NRDS | DCTH |
|---|---|---|
| Price | $9.53 | $16.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.00 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 569.7K | 367.8K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.42 | ★ 107.53 |
| EPS | ★ 0.37 | 0.04 |
| Revenue | ★ $836,600,000.00 | N/A |
| Revenue This Year | $10.13 | $24.54 |
| Revenue Next Year | $7.11 | $33.15 |
| P/E Ratio | ★ $25.49 | $397.75 |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $7.33 | $8.12 |
| 52 Week High | $16.24 | $17.42 |
| Indicator | NRDS | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 57.71 |
| Support Level | $9.45 | $9.98 |
| Resistance Level | $9.75 | $17.42 |
| Average True Range (ATR) | 0.27 | 0.39 |
| MACD | -0.08 | -0.20 |
| Stochastic Oscillator | 20.95 | 52.60 |
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.